Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...
Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people ...
45mon MSN
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback